Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Medicinal Chemistry Strategies for the Development of Bruton’s Tyrosine Kinase Inhibitors against Resistance
Shan‐Liang Sun, Shi-Han Wu, Ji-Bo Kang, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 11, pp. 7415-7437
Closed Access | Times Cited: 25

Showing 25 citing articles:

Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton’s Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies
Daniel Robbins, Mark Noviski, Ying Siow Tan, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 4, pp. 2321-2336
Open Access | Times Cited: 32
Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials
Dariusz Rozkiewicz, Justyna Magdalena Hermanowicz, Iwona Kwiatkowska, et al.
Molecules (2023) Vol. 28, Iss. 5, pp. 2400-2400
Open Access | Times Cited: 37
Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations
Zixuan Wang, Qingqing Li, Jiao Cai, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 6, pp. 4346-4375
Closed Access | Times Cited: 7
Insight into Janus kinases specificity: From molecular architecture to cancer therapeutics
Tian‐Hua Wei, Meng‐Yi Lu, Sihui Yao, et al.
MedComm – Oncology (2024) Vol. 3, Iss. 1
Open Access | Times Cited: 6
BTK inhibitors resistance in B cell malignancies: Mechanisms and potential therapeutic strategies
Xin Liu, Yufan Lin, Qiqi Zhuang, et al.
Blood Reviews (2025), pp. 101273-101273
Closed Access
Design and application of a fluorescent probe for imaging of endogenous Bruton’s tyrosine kinase with preserved enzymatic activity
Anna P. Valaka, Helena Filipsson Nyström, Liliana Håversen, et al.
RSC Chemical Biology (2025)
Open Access
Overcoming cancer therapy resistance: From drug innovation to therapeutics
Jinrui Wei, Meng‐Yi Lu, Tian‐Hua Wei, et al.
Drug Resistance Updates (2025), pp. 101229-101229
Closed Access
Discovery of Novel Potent and Fast BTK PROTACs for the Treatment of Osteoclasts-Related Inflammatory Diseases
Junli Huang, Zeli Ma, Xiaopeng Peng, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 4, pp. 2438-2465
Closed Access | Times Cited: 4
Discovery of SILA-123 as a Highly Potent FLT3 Inhibitor for the Treatment of Acute Myeloid Leukemia with Various FLT3 Mutations
Tian‐Hua Wei, Zixuan Wang, Meng‐Yi Lu, et al.
Journal of Medicinal Chemistry (2024)
Closed Access | Times Cited: 2
Synthesis and Preclinical Evaluation of a Novel Fluorine-18-Labeled Tracer for Positron Emission Tomography Imaging of Bruton’s Tyrosine Kinase
Kaixuan Li, Mingqian Wang, Melike Akoglu, et al.
ACS Pharmacology & Translational Science (2023) Vol. 6, Iss. 3, pp. 410-421
Open Access | Times Cited: 5
Discovery of Thieno[3,2-d]pyrimidine derivatives as potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) kinase
Yunxin Duan, Haodong Cheng, Lili Zhuang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 255, pp. 115370-115370
Closed Access | Times Cited: 5
Determination and mechanism of Xiao-Ai Jie-Du decoction against diffuse large B-cell lymphoma: In silico and In vitro studies
Xin-Zhuo Zhan, Tian‐Hua Wei, Yu-Qi Yin, et al.
Journal of Ethnopharmacology (2023) Vol. 319, pp. 117271-117271
Closed Access | Times Cited: 5
The current strategies of optimization of oseltamivir against mutant neuraminidases of influenza A：A review
Kuanglei Wang, Huicong Zhang, Yongshou Tian
European Journal of Medicinal Chemistry (2022) Vol. 243, pp. 114711-114711
Closed Access | Times Cited: 9
Design and synthesis 1H-Pyrrolo[2,3-b]pyridine derivatives as FLT3 inhibitors for the treatment of Acute myeloid Leukemia
Tian‐Hua Wei, Yun Zhou, Jin Yang, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 100, pp. 117631-117631
Closed Access | Times Cited: 1
Discovery of a novel BTK inhibitor S-016 and identification of a new strategy for the treatment of lymphomas including BTK inhibitor-resistant lymphomas
Peiran Song, Zhi-peng Wan, Gege Huang, et al.
Acta Pharmacologica Sinica (2024)
Closed Access | Times Cited: 1
Modulating JAK2/STAT3 signaling by quercetin in Qiling Baitouweng Tang: a potential therapeutic approach for diffuse large B-cell lymphoma
Xin-Zhuo Zhan, Tian‐Hua Wei, Chen Huang, et al.
Molecular Diversity (2024)
Closed Access | Times Cited: 1
Synthesis and biological evaluation of 4-(4-aminophenyl)-6-methylisoxazolo[3,4-b] pyridin-3-amine covalent inhibitors as potential agents for the treatment of acute myeloid leukemia
Ji-Bo Kang, Lu Chen, Xuejiao Leng, et al.
Bioorganic & Medicinal Chemistry (2022) Vol. 70, pp. 116937-116937
Closed Access | Times Cited: 8
Discovery of 4‐(4‐aminophenyl)‐6‐phenylisoxazolo[3,4‐b]pyridine‐3‐amine derivatives as novel FLT3 covalent inhibitors for the intervention of acute myeloid leukemia
Qing‐Xin Wang, Yibo Wang, Jiu‐Kai Sha, et al.
Drug Development Research (2023) Vol. 84, Iss. 2, pp. 296-311
Closed Access | Times Cited: 4
Discovery of JNJ-64264681: A Potent and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase
Mark S. Tichenor, John J. M. Wiener, Navin Rao, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 21, pp. 14326-14336
Closed Access | Times Cited: 6
Investigating the ibrutinib resistance mechanism of L528W mutation on Brutonʼs tyrosine kinase via molecular dynamics simulations
Xu BiYu, Luguang Liang, Yi-Rong Jiang, et al.
Journal of Molecular Graphics and Modelling (2023) Vol. 126, pp. 108623-108623
Closed Access | Times Cited: 3
Development of novel hydrazidoarylaminopyrimidine-based BTK/FLT3 dual inhibitors with potent in vivo anti-hematological malignancies effects
Fansheng Ran, Xudong Xie, Qilin Wu, et al.
European Journal of Medicinal Chemistry (2022) Vol. 245, pp. 114913-114913
Closed Access | Times Cited: 5
Medicinal perspectives and structure-activity relationship studies of pyrimidine based Bruton’s tyrosine kinase inhibitors as potential anticancer agents
Keshav Taruneshwar Jha, Abhimannu Shome, Chahat, et al.
Process Biochemistry (2023) Vol. 132, pp. 308-322
Closed Access | Times Cited: 2
Advances in protein kinase drug discovery through targeting gatekeeper mutations
Jing Guo, Yang Zhou, Xiaoyun Lu
Expert Opinion on Drug Discovery (2023) Vol. 18, Iss. 12, pp. 1349-1366
Closed Access | Times Cited: 2
Computer-aided investigation of Traditional Chinese Medicine mechanisms: A case study of San-Ao decoction in asthma treatment
M Jiang, Yan Lu, Mengwen Li, et al.
Computers in Biology and Medicine (2023) Vol. 169, pp. 107868-107868
Closed Access | Times Cited: 2
Exploring the landscape of post-translational modification in drug discovery
Yuhao Cao, Tianyi Yu, Zhiguang Zhu, et al.
Pharmacology & Therapeutics (2024) Vol. 265, pp. 108749-108749
Closed Access
Page 1

Scroll to top